Oryzon Genomics S.A. (ORY.MC)
EUR 1.59
(-3.98%)
EUR 1.59
(-3.98%)
| Year | Operating Expenses | Operating Expenses Growth |
|---|---|---|
| 2023 | 18.49 Million EUR | -10.75% |
| 2022 | 20.72 Million EUR | 22.8% |
| 2021 | 16.87 Million EUR | 27.04% |
| 2020 | 13.28 Million EUR | 25.93% |
| 2019 | 10.54 Million EUR | 0.0% |
| Year | Operating Expenses | Operating Expenses Growth |
|---|---|---|
| 2024 Q2 | 3.1 Million EUR | 2.86% |
| 2024 Q3 | 2.79 Million EUR | -9.9% |
| 2024 Q1 | 3.24 Million USD | -32.73% |
| 2023 Q4 | 4.48 Million EUR | 6.98% |
| 2023 FY | 18.49 Million EUR | -10.75% |
| 2023 Q3 | 4.18 Million EUR | -13.79% |
| 2023 Q2 | 4.85 Million EUR | -5.29% |
| 2023 Q1 | 5.13 Million EUR | 0.0% |
| 2022 Q4 | - EUR | 0.0% |
| 2022 FY | 20.72 Million EUR | 22.8% |
| 2021 FY | 16.87 Million EUR | 27.04% |
| 2020 FY | 13.28 Million EUR | 25.93% |
| 2019 FY | 10.54 Million EUR | 0.0% |
| Name | Operating Expenses | Operating Expenses Difference |
|---|---|---|
| ABIONYX Pharma SA | 4.17 Million EUR | -342.832% |
| ABIVAX Société Anonyme | 127.37 Million EUR | 85.478% |
| Adocia SA | 15.62 Million EUR | -18.351% |
| Aelis Farma SA | 18.81 Million EUR | 1.71% |
| Biophytis S.A. | 14.33 Million EUR | -29.053% |
| Advicenne S.A. | 8.21 Million EUR | -125.163% |
| genOway Société anonyme | 16.73 Million EUR | -10.508% |
| IntegraGen SA | 5.35 Million EUR | -245.578% |
| Medesis Pharma S.A. | 1.56 Million EUR | -1082.247% |
| Neovacs S.A. | 10.34 Million EUR | -78.828% |
| NFL Biosciences SA | 4.37 Million EUR | -322.854% |
| Plant Advanced Technologies SA | 2.76 Million EUR | -569.009% |
| Quantum Genomics Société Anonyme | 1.71 Million EUR | -976.687% |
| Sensorion SA | 27.05 Million EUR | 31.628% |
| Theranexus Société Anonyme | 3 Million EUR | -515.547% |
| TME Pharma N.V. | 5.49 Million EUR | -236.495% |
| Valbiotis SA | 9.86 Million EUR | -87.426% |
| TheraVet SA | 1.64 Million EUR | -1024.914% |
| Valerio Therapeutics Société anonyme | 20.32 Million EUR | 8.971% |
| argenx SE | 1.34 Billion EUR | 98.622% |
| BioSenic S.A. | 7.58 Million EUR | -143.929% |
| Celyad Oncology SA | 8.49 Million EUR | -117.869% |
| DBV Technologies S.A. | 89.4 Million EUR | 79.311% |
| Galapagos NV | 327.98 Million EUR | 94.36% |
| Genfit S.A. | 54.8 Million EUR | 66.249% |
| GeNeuro SA | 14.35 Million EUR | -28.834% |
| Hyloris Pharmaceuticals SA | 17.98 Million EUR | -2.836% |
| Innate Pharma S.A. | 64.57 Million EUR | 71.353% |
| Inventiva S.A. | 120.18 Million EUR | 84.61% |
| MaaT Pharma SA | 21.59 Million EUR | 14.357% |
| MedinCell S.A. | 32.92 Million EUR | 43.815% |
| Nanobiotix S.A. | 58.92 Million EUR | 68.61% |
| Onward Medical N.V. | 20.64 Million EUR | 10.404% |
| OSE Immunotherapeutics SA | 23.58 Million EUR | 21.586% |
| Oxurion NV | 12.21 Million EUR | -51.442% |
| Pharming Group N.V. | 204.24 Million EUR | 90.944% |
| Poxel S.A. | 28.76 Million EUR | 35.696% |
| GenSight Biologics S.A. | 32.66 Million EUR | 43.365% |
| Transgene SA | 31.23 Million EUR | 40.773% |
| Financière de Tubize SA | 114.38 Thousand EUR | -16070.355% |
| UCB SA | 2.94 Billion EUR | 99.371% |
| Valneva SE | 134.92 Million EUR | 86.291% |
| Vivoryon Therapeutics N.V. | 24.69 Million EUR | 25.089% |